Krieger, Britta http://orcid.org/0000-0002-6364-2743
Schneider-Gold, Christiane
Genç, Erhan
Güntürkün, Onur
Prehn, Christian
Bellenberg, Barbara
Lukas, Carsten
Funding for this research was provided by:
Katholisches Klinikum Bochum gGmbh
Article History
Received: 27 March 2024
Revised: 7 June 2024
Accepted: 10 June 2024
First Online: 19 June 2024
Declarations
:
: C.S.G. has received consulting and/or speaker’s honoraria from Alexion Pharmaceuticals, Amicus Therapeutics, Bayer Vital, Hormosan Pharma, Immunovant, Janssen, Lupin Pharmaceuticals, Roche, Sanofi-Genzyme, and UCB outside the submitted work. B.B. received financial support by the German Federal Ministry for Education and Research, BMBF, German Competence Network Multiple Sclerosis (KKNMS). C.L. received a research grant by the German Federal Ministry for Education and Research, BMBF, German Competence Network Multiple Sclerosis (KKNMS), grant no. 01GI1601I, and received consulting and speaker’s honoraria from Biogen Idec, Bayer Schering, Daiichi Sanykyo, Merck Serono, Novartis, Sanofi, Genzyme and TEVA. None of the other authors has any conflict of interest to disclose.
: The study was approved by the local ethics committee of the Ruhr University Bochum (No. 20–7045, 06/10/2020), and all patients provided written informed consent prior to study participation.